NCT06674538
Clinical Trial to Treat Stage IV Cancer Patients
Enrolling by Invitation
PHASE1Ages 18+InterventionalTreatmentMoonshot Antibodies
~12 participants
Updated 2025-09-22 on ClinicalTrials.gov
What's tested:Moonshot antibodies
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety: Frequency of Grade III or greater adverse events
Measured over From first dose of treatment through endpoint evaluation at 6 months
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- David Krag, MD · STUDY_CHAIR · Moonshot Antibodies
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Safety: Frequency of Grade III or greater adverse eventsFrom first dose of treatment through endpoint evaluation at 6 months
Frequency of Grade III or greater adverse events